State Street’s Processa Pharmaceuticals PCSA Stock Holding History

State Street’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-86	Closed	-$14.3K	–	4395
2023 Q4	$14.3K	Hold	86	–	–	﹤0.01%	4371
2023 Q3	$10.9K	Hold	86	–	–	﹤0.01%	4502
2023 Q2	$21.3K	Hold	86	–	–	﹤0.01%	4586
2023 Q1	$22.7K	Hold	86	–	–	﹤0.01%	4668
2022 Q4	$47.1K	Hold	86	–	–	﹤0.01%	4571
2022 Q3	$97K	Hold	86	–	–	﹤0.01%	4474
2022 Q2	$120K	Buy	86 +3	+4%	+$4.11K	﹤0.01%	4441
2022 Q1	$125K	Hold	83	–	–	﹤0.01%	4570
2021 Q4	$203K	Hold	83	–	–	﹤0.01%	4345
2021 Q3	$356K	Buy	83 +50	+152%	+$171K	﹤0.01%	4110
2021 Q2	$136K	Buy	+33	New	+$128K	﹤0.01%	4304

Other funds holding PCSA

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MSG

Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

MIM

Macroview Investment Management Bethesda, Maryland $162M AUM 22.52% 1-Year Est. Return

State Street's PCSA Position: Q1 2024 in Review

State Street sold out of Processa Pharmaceuticals (PCSA) in Q1 2024, closing a stake of 86 shares — an estimated $14.3K sold.

State Street first reported a position in PCSA in Q2 2021 and held it in 11 quarters. The position peaked at $356K in Q3 2021. 9 funds tracked by Wall St. Rank hold PCSA as of Q1 2024.

State Street reported no remaining Processa Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
State Street sold 86 Processa Pharmaceuticals shares in Q1 2024, an estimated $14.3K.
State Street first reported a position in Processa Pharmaceuticals in Q2 2021 and held it in 11 quarters.
State Street's Processa Pharmaceuticals position peaked at $356K in Q3 2021.
9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.